ProQR Therapeutics (PRQR) Total Current Liabilities (2013 - 2026)
ProQR Therapeutics (PRQR) posted Total Current Liabilities of $41.0 million for Q1 2026, up 8.69% sequentially from $37.8 million in Q4 2025, and up 15.73% YoY from $35.5 million in Q1 2025.
ProQR Therapeutics (PRQR) Total Current Liabilities (2013 - 2026) Analysis & Trends
ProQR Therapeutics has reported Total Current Liabilities for 14 years, with the latest figure at $41.0 million in Q1 2026.
- Quarterly Total Current Liabilities rose 15.73% year-over-year to $41.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $41.0 million (up 15.73% YoY) and the FY2025 annual result came in at $37.8 million, down 9.16% from the prior year.
- Total Current Liabilities rose to $41.0 million in Q1 2026 per PRQR's latest filing, from $37.8 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $43.5 million in Q3 2024 and troughed at $18.4 million in Q1 2023.
- A 5-year average of $33.3 million and a median of $36.8 million in 2023 frame the typical range for Total Current Liabilities.
- The widest YoY moves for Total Current Liabilities: up 210168.06% in 2022, down 33.52% in 2022.
- Over 5 years, Total Current Liabilities stood at $21.4 million in 2022, then soared by 71.86% to $36.8 million in 2023, then climbed by 12.96% to $41.6 million in 2024, then fell by 9.16% to $37.8 million in 2025, then increased by 8.69% to $41.0 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $41.0 million, $37.8 million, and $38.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | ProQR Therapeutics | 206.80 Mn | 111.86 Mn | - | 41.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 41.04 Mn |
| Dec 31, 2025 | 37.76 Mn |
| Sep 30, 2025 | 38.74 Mn |
| Jun 30, 2025 | 37.45 Mn |
| Mar 31, 2025 | 35.47 Mn |
| Dec 31, 2024 | 41.57 Mn |
| Sep 30, 2024 | 43.53 Mn |
| Jun 30, 2024 | 40.15 Mn |
| Mar 31, 2024 | 37.39 Mn |
| Dec 31, 2023 | 36.80 Mn |
| Sep 30, 2023 | 29.01 Mn |
| Jun 30, 2023 | 25.02 Mn |
| Mar 31, 2023 | 18.42 Mn |
| Dec 31, 2022 | 21.41 Mn |
| Sep 30, 2022 | 27.20 Mn |
| Jun 30, 2022 | 28.96 Mn |
| Mar 31, 2022 | 26.62 Mn |
| Dec 31, 2021 | 31.57 Mn |
| Sep 30, 2021 | 40.91 Mn |
| Jun 30, 2021 | 14.90 Mn |